Twist Bioscience initiated with an Overweight at Stephens

Stephens analyst Steven Etoch initiated coverage of Twist Bioscience (TWST) with an Overweight rating and $41 price target Twist operates a differentiated, technology-driven DNA synthesis platform with proprietary silicon chip technology, inspired by semiconductor manufacturing, that provides advantages in cost, speed, and scale. While competition remains intense, Twist’s cost leadership and prior investments are driving share gains and although the path to profitability is “not fully de-risked,” the firm sees a growing line of sight driven by strategic execution and commercial momentum, the analyst tells investors.